Clinical Oncology Next Generation Sequencing

Global Clinical Oncology Next Generation Sequencing Market to Reach US$1.2 Billion by 2030

The global market for Clinical Oncology Next Generation Sequencing estimated at US$489.9 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 15.8% over the analysis period 2024-2030. Whole Genome Sequencing, one of the segments analyzed in the report, is expected to record a 17.7% CAGR and reach US$733.2 Million by the end of the analysis period. Growth in the Whole Exome Sequencing segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$133.5 Million While China is Forecast to Grow at 21.3% CAGR

The Clinical Oncology Next Generation Sequencing market in the U.S. is estimated at US$133.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$262.0 Million by the year 2030 trailing a CAGR of 21.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.5% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global Clinical Oncology Next Generation Sequencing Market – Key Trends & Drivers Summarized

Why Is Next Generation Sequencing Transforming the Clinical Oncology Landscape?

Next Generation Sequencing (NGS) has revolutionized clinical oncology by enabling a deeper, more precise understanding of cancer at the molecular level. Unlike traditional diagnostic methods, NGS allows for the comprehensive profiling of cancer genomes, identifying genetic mutations, copy number variations, gene fusions, and other biomarkers critical to tumor characterization. As cancer treatment increasingly shifts toward precision medicine, NGS plays a central role in guiding personalized therapies, predicting treatment response, and monitoring disease progression or recurrence. The ability of NGS to process large volumes of genomic data rapidly and cost-effectively has significantly accelerated its adoption in clinical oncology practices. Oncologists are now using NGS-based panels for companion diagnostics, targeted therapy selection, immunotherapy eligibility, and even hereditary cancer screening. This molecular insight is transforming how cancers are diagnosed, classified, and treated, leading to better patient outcomes and more efficient use of healthcare resources. As cancer incidence continues to rise globally, NGS is becoming an indispensable tool in modern oncology workflows, enabling precision-driven decision-making at every stage of care.

How Are Technological Advancements and Platform Innovations Fueling Market Growth?

The clinical oncology NGS market is being propelled by rapid technological advancements and continuous innovation in sequencing platforms, workflows, and data interpretation tools. The evolution of high-throughput sequencing technologies—ranging from whole-genome and whole-exome sequencing to targeted gene panels—is offering flexible and scalable solutions tailored to diverse clinical needs. Improvements in sequencing speed, accuracy, and affordability are making NGS more accessible across healthcare settings, from academic centers to community oncology clinics. Advanced bioinformatics platforms are now integrated into clinical pipelines, enabling automated variant calling, interpretation, and reporting in compliance with international guidelines such as those by the AMP, ASCO, and CAP. Moreover, the development of liquid biopsy-based NGS tests—using circulating tumor DNA (ctDNA)—is gaining momentum as a non-invasive, real-time tool for cancer detection and monitoring. Miniaturized sequencing platforms and cloud-based data storage solutions are further simplifying clinical implementation. These technological strides are not only reducing turnaround times and lowering costs but also expanding the clinical utility of NGS beyond advanced-stage cancers into early detection, screening, and longitudinal monitoring.

What Role Do Clinical Practice Trends, Regulatory Frameworks, and Regional Dynamics Play in Market Expansion?

The adoption of NGS in clinical oncology is shaped by a convergence of clinical practice trends, regulatory guidelines, and region-specific healthcare dynamics. There is a growing shift toward standardized genomic testing as part of routine oncology diagnostics, driven by increasing awareness among clinicians about the prognostic and therapeutic implications of genetic mutations. Regulatory authorities such as the FDA, EMA, and PMDA are accelerating approvals for NGS-based companion diagnostics, facilitating integration into clinical practice. Simultaneously, payer acceptance and evolving reimbursement policies for genomic tests are enhancing affordability and adoption across key markets. In developed regions like North America and Western Europe, high digital infrastructure and advanced healthcare ecosystems support widespread use of clinical NGS, while in Asia-Pacific and Latin America, market growth is being fueled by government-led genomics initiatives, expanding oncology care infrastructure, and increasing investments by private healthcare providers. Collaborations between diagnostics companies, pharmaceutical firms, and academic research institutions are also driving innovation and market penetration. Despite challenges such as data interpretation complexity and skilled workforce shortages, the global shift toward evidence-based oncology care is firmly positioning NGS as a clinical mainstay.

What Are the Core Growth Drivers Shaping the Clinical Oncology NGS Market?

The growth in the clinical oncology next generation sequencing market is driven by several factors rooted in technological advancement, evolving clinical needs, and changing healthcare delivery models. The rising global cancer burden and the shift toward precision oncology are significantly increasing the demand for comprehensive molecular profiling solutions. Technological breakthroughs in sequencing chemistry, multiplexing, and automation are making NGS faster, more reliable, and increasingly cost-effective. The emergence of novel testing formats—such as liquid biopsies and single-cell sequencing—is expanding NGS application areas beyond diagnostics into real-time monitoring and minimal residual disease detection. Expanding use of NGS for therapy guidance, particularly in immuno-oncology and targeted treatments, is boosting its clinical relevance. Growing availability of companion diagnostics and regulatory approvals for tumor-specific NGS panels are accelerating adoption across treatment centers. The increasing integration of NGS into electronic medical records and digital pathology workflows is enhancing clinical decision support. Moreover, the proliferation of public and private genomic databases, along with collaborative research ecosystems, is enriching the interpretation of NGS data. Patient awareness, demand for personalized care, and growing healthcare investments in molecular diagnostics are further propelling the global expansion of the clinical oncology NGS market.

SCOPE OF STUDY:

The report analyzes the Clinical Oncology Next Generation Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology Type (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing and Resequencing); Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis); Application (Screening Application, Companion Diagnostics Application, Other Diagnostics Application); End-Use (Hospitals End-Use, Clinics End-Use, Laboratories End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

• Agilent Technologies, Inc.
• Becton, Dickinson and Company (BD)
• Beijing Genomics Institute (BGI)
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Caris Life Sciences
• Eurofins Scientific S.E.
• F. Hoffmann-La Roche Ltd.
• Foundation Medicine, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Oxford Nanopore Technologies Ltd.
• Pacific Biosciences of California, Inc.
• Partek Incorporated
• PerkinElmer, Inc.
• Qiagen N.V.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Zymo Research Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.